Pharma packaging company Schott Pharma has unveiled plans to establish a new manufacturing facility in Wilson, North Carolina. Schott Pharma says the $371 million investment in the U.S. facility will create more than 400 jobs in the region and significantly expand the company’s presence in the U.S., an increasingly important strategic market for the German…
Pfizer gives up on Washington state manufacturing plant project
Pfizer recently announced that it will wind down the construction of an Everett, Washington cancer therapies manufacturing plant that it inherited through its $43 billion acquisition of Seagen last year. Over the summer before the acquisition closure in December 2023, Seagen had inked a $215 million deal with contractor Skanksa to build the 270,000-square-foot facility,…
Amgen opens AI-enabled Ohio biomanufacturing facility
Earlier this year, NVIDIA and Amgen revealed plans to analyze one of the world’s largest human datasets using AI models trained on an NVIDIA DGX SuperPOD in Iceland. Now, Amgen is signaling its continued commitment to cutting-edge tech with a ribbon cutting for an advanced biomanufacturing facility in New Albany, Ohio. Known as Amgen Ohio,…
AbbVie is expanding its Singapore biologics plant
AbbVie (NYSE: ABBV) recently announced that it will spend $223 million to expand its Singapore biologics manufacturing facility. Construction will commence immediately, with the facilities coming online in 2026. The added facilities will create 100 new jobs at the plant, boosting total employment to more than 500 positions in manufacturing, quality assurance, supply chain, engineering…
AstraZeneca invests $300 million to establish new cell therapy manufacturing facility in Maryland
Maryland Governor Wes Moore announced that AstraZeneca would invest $300 million to construct a new manufacturing facility in Rockville, a city with roughly 70,000 inhabitants that is about 17 miles from Washington, D.C. The facility will focus on cell therapies for cancer treatment. The 84,000 square-foot facility, slated for completion in 2026, will enable global…
A guide to implementing operational excellence in drug development
When it comes to drug development and manufacturing, operational excellence (OpEx) is critical for success at all levels. It can help establish a culture of continuous improvement and innovation while supporting data quality, compliance, customer satisfaction, and more. It can even impact external perceptions of the company and confidence in the strength of the business.…
Pharma manufacturing sees wave of investments in Europe
Over the past three months, the pharma sector has seen a string of investments in manufacturing facilities, especially in Europe. While the European economy lost momentum in 2023 owing to a high cost of living, weak external demand, and monetary tightening, the prospects for growth remain stronger with the EU GDP growth forecast to improve…
Novartis opens new radioligand therapy manufacturing facility in Indianapolis
Novartis today announced the expansion of its radioligand therapy (RLT) manufacturing capabilities with a new facility in Indianapolis. The Basil, Switzerland–based pharma giant said it has received FDA approval for commercial manufacturing in Indianapolis of its RLT therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to treat advanced metastatic prostate cancer. The new 70,000-square foot facility…
Pfizer’s $3.5B cost-cutting strategy hits Peapack site in New Jersey
After news emerged regarding Pfizer’s plans to close sites in North Carolina, the company is adding New Jersey to the list. The company expects its Peapack facility to cease operations in early 2024. A Worker Adjustment and Retraining Notification(WARN) Notice notes that 791 workers could potentially be cut from its Somerset County corporate office. The…
FDA resolves drug shortage for Novartis’ prostate cancer drug Pluvicto
Novartis has announced that the FDA has resolved the drug shortage status for Pluvicto (lutetium Lu 177 vipivotide tetraxetan). The development comes after Novartis significantly scaled up production, more than doubling its weekly production capacity since May. The company initially halted production of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) along with Lutathera (USAN: lutetium Lu…